Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Reseña (Review)

Health care services use among long-term breast cancer survivors: a systematic review

  • Jansana, A.
  • Posso, M.
  • Guerrero, I.
  • Prados-Torres, A.
  • Del Cura, M.I.
  • Castells, X.
  • Sala, M.
Purpose: Long-term breast cancer survivors are women surviving at least 5 years after diagnosis. This systematic review aimed to summarize the main characteristics and patterns of healthcare service use (frequency of visits, health providers visited, and preventive care performed) among long-term breast cancer survivors. Methods: We used standard Cochrane Collaboration methods and searched the MEDLINE and EMBASE databases up to January 2018. We included English language observational studies reporting health service use among long-term cancer survivors. The quality of the studies was appraised through the ROBINS-I assessment tool. Two independent reviewers performed both the study quality assessment and the data extraction. Results: A total of 23 observational studies were included that reported data on health services use by long-term breast cancer survivors. Despite heterogeneity among studies, about half of them reported that breast cancer survivors visited a medical provider at least once a year, as recommended by breast cancer survival guidelines. Although survivors visited medical providers with the recommended frequency, a substantial number used specialist care instead of primary care during follow-up. The results showed underuse of the recommended annual mammogram. Conclusions: Long-term breast cancer survivors differ in their health services use with regard to the frequency of visits as well as the health providers seen. Our results indicate the need for active surveillance through primary care providers in coordination with specialized care. Implications for cancer survivors: This review could help to standardize the management of breast cancer survivors and decision-makers to adapt their guidelines and clinical protocols.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Use of real-world data to study health services utilisation and comorbidities in long-term breast cancer survivors (the SURBCAN study): study protocol for a longitudinal population-based cohort study

  • Jansana, A.
  • Del Cura, I.
  • Prados-Torres, A.
  • Sanz Cuesta, T.
  • Poblador-Plou, B.
  • Gimeno Miguel, A.
  • Lanzuela, M.
  • Ibañez, B.
  • Tamayo, I.
  • Moreno-Iribas, C.
  • Padilla-Ruiz, M.
  • Redondo, M.
  • Comas, M.
  • Domingo, L.
  • Díaz-Holgado, A.
  • Salamanca, F.J.
  • Castells, X.
  • Sala, M.
  • SURBCAN, group
INTRODUCTION: Breast cancer has become a chronic disease due to survival improvement and the need to monitor the side effects of treatment and the disease itself. The aim of the SURBCAN study is to describe comorbidity, healthcare services use and adherence to preventive recommendations in long-term breast cancer survivors and to compare them with those in women without this diagnosis in order to improve and adapt the care response to this group of survivors. METHODS AND ANALYSIS: Population-based retrospective cohort study using real-world data from cancer registries and linked electronic medical records in five Spanish regions. Long-term breast cancer survivors diagnosed between 2000 and 2006 will be identified and matched by age and administrative health area with women without this diagnosis. Sociodemographic and clinical variables including comorbidities and variables on the use of health services between 2012 and 2016 will be obtained from databases in primary and hospital care. Health services use will be assessed through the annual number of visits to primary care professionals and to specialists and through annual imaging and laboratory tests. Factors associated with healthcare utilisation and comorbidities will be analysed using multilevel logistic regression models. Recruitment started in December 2018. ETHICS AND DISSEMINATION: This study was approved by the Ethics Committee of Parc de Salut Mar. The results of the study will be published in a peer-reviewed journal and will be presented at national and international scientific conferences and at patient associations. TRIAL REGISTRATION NUMBER: This protocol is registered in Clinical Trials.gov (identifier: NCT03846999).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Factors associated with readmissions in women participating in screening programs and treated for breast cancer, A retrospective cohort study

  • Miret, Carme|||0000-0001-6154-3998
  • Domingo, Laia|||0000-0003-4420-0891
  • Louro, Javier|||0000-0002-2985-3301
  • Barata, Teresa
  • Baré i Mañas, Marisa|||0000-0001-8085-2833
  • Ferrer, Joana
  • Carmona-Garcia, M. Carmen|||0000-0002-4011-9474
  • Castells, Xavier|||0000-0002-2528-0382
  • Sala, Maria|||0000-0002-9955-8746
Background: We aimed to identify the risk factors associated with early, late and long-term readmissions in women diagnosed with breast cancer participating in screening programs. Methods: We performed a multicenter cohort study of 1055 women aged 50-69 years participating in Spanish screening programs, diagnosed with breast cancer between 2000 and 2009, and followed up to 2014. Readmission was defined as a hospital admission related to the disease and/or treatment complications, and was classified as early (< 30 days), late (30 days-1 year), or long-term readmission (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exploring the Role of Breast Density on Cancer Prognosis among Women Attending Population-Based Screening Programmes

  • Domingo, Laia|||0000-0003-4420-0891
  • Sala, Maria|||0000-0002-9955-8746
  • Louro, Javier|||0000-0002-2985-3301
  • Baré i Mañas, Marisa|||0000-0001-8085-2833
  • Barata, Teresa
  • Ferrer, Joana
  • Carmona-Garcia, M. Carmen|||0000-0002-4011-9474
  • Comas Serrano, Mercè|||0000-0003-1926-2740
  • Castells, Xavier|||0000-0002-2528-0382
Background. Our aim was to assess the role of breast density on breast cancer mortality and recurrences, considering patient and tumour characteristics and the treatments received among women attending population-based screening programmes. Methods. We conducted a retrospective cohort study among women aged 50-69 years attending population-based screening programmes, diagnosed with invasive breast cancer between 2000 and 2009, and followed up to 2014. Breast density was categorised as low density (≤25% dense tissue), intermediate density (25-50%), and high density (≥50%). Cox proportional hazards regression models were fitted to estimate the adjusted hazard ratios (aHR) and 95% confidence intervals (95% CI) for death and recurrences, adjusting by patient characteristics, mode of detection (screen-detected vs. interval cancer), and tumour features. Results. The percentage of deaths and recurrences was higher among women with intermediate- and high-density breasts than among women with low-density breasts (p=0.011 for death; p=0.037 for recurrences). Adjusted Cox proportional hazards regression models revealed that women with intermediate- and high-density breasts had a higher risk of death than women with low-density breasts, being statistically significant for intermediate densities (aHR = 2.19 [95% CI: 1.16-4.13], aHR = 1.44 [95% CI: 0.67-3.1], respectively). No association was found between breast density and recurrences. Conclusions. Breast density was associated with a higher risk of death, but not of recurrences, among women participating in breast cancer screening. These findings reinforce the need to improve screening sensitivity among women with dense breasts and to routinely assess breast density, not only for its role as a risk factor for breast cancer but also for its potential influence on cancer prognosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

A systematic review and quality assessment of individualised breast cancer risk prediction models

  • Louro, Javier|||0000-0002-2985-3301
  • Posso, Margarita|||0000-0002-5053-257X
  • Hilton Boon, Michele|||0000-0002-2240-7923
  • Román, Marta|||0000-0001-9076-8918
  • Domingo, Laia|||0000-0003-4420-0891
  • Castells, Xavier|||0000-0002-2528-0382
  • Sala, Maria|||0000-0002-9955-8746
Individualised breast cancer risk prediction models may be key for planning risk-based screening approaches. Our aim was to conduct a systematic review and quality assessment of these models addressed to women in the general population. We followed the Cochrane Collaboration methods searching in Medline, EMBASE and The Cochrane Library databases up to February 2018. We included studies reporting a model to estimate the individualised risk of breast cancer in women in the general population. Study quality was assessed by two independent reviewers. Results are narratively summarised. We included 24 studies out of the 2976 citations initially retrieved. Twenty studies were based on four models, the Breast Cancer Risk Assessment Tool (BCRAT), the Breast Cancer Surveillance Consortium (BCSC), the Rosner & Colditz model, and the International Breast Cancer Intervention Study (IBIS), whereas four studies addressed other original models. Four of the studies included genetic information. The quality of the studies was moderate with some limitations in the discriminative power and data inputs. A maximum AUROC value of 0.71 was reported in the study conducted in a screening context. Individualised risk prediction models are promising tools for implementing risk-based screening policies. However, it is a challenge to recommend any of them since they need further improvement in their quality and discriminatory capacity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Differences in breast cancer risk after benign breast disease by type of screening diagnosis

  • Louro, Javier|||0000-0002-2985-3301
  • Román, Marta|||0000-0001-9076-8918
  • Posso, Margarita|||0000-0002-5053-257X
  • Comerma, Laura|||0000-0002-0249-4636
  • Vidal, Carmen|||0000-0003-2768-2710
  • Saladié, Francina|||0000-0002-1783-4066
  • Alcántara Souza, Rodrigo|||0000-0003-4365-5640
  • Sánchez Movellán, Mar
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • del Riego, Javier|||0000-0001-9200-3505
  • Ferrer, Joana
  • Peñalva, Lupe
  • Bargalló, Xavier
  • Prieto, Miguel
  • Sala, Maria|||0000-0002-9955-8746
  • Castells, Xavier|||0000-0002-2528-0382
We aimed to assess differences in breast cancer risk across benign breast disease diagnosed at prevalent or incident screens. We conducted a retrospective cohort study with data from 629,087 women participating in a long-standing population-based breast cancer screening program in Spain. Each benign breast disease was classified as non-proliferative, proliferative without atypia, or proliferative with atypia, and whether it was diagnosed in a prevalent or incident screen. We used partly conditional Cox hazard regression to estimate the adjusted hazard ratios of the risk of breast cancer. Compared with women without benign breast disease, the risk of breast cancer was significantly higher (p-value = 0.005) in women with benign breast disease diagnosed in an incident screen (aHR, 2.67; 95%CI: 2.24-3.19) than in those with benign breast disease diagnosed in a prevalent screen (aHR, 1.87; 95%CI: 1.57-2.24). The highest risk was found in women with a proliferative benign breast disease with atypia (aHR, 4.35; 95%CI: 2.09-9.08, and 3.35; 95%CI: 1.51-7.40 for those diagnosed at incident and prevalent screens, respectively), while the lowest was found in women with non-proliferative benign breast disease (aHR, 2.39; 95%CI: 1.95-2.93, and 1.63; 95%CI: 1.32-2.02 for those diagnosed at incident and prevalent screens, respectively). Our study showed that the risk of breast cancer conferred by a benign breast disease differed according to type of screen (prevalent or incident). To our knowledge, this is the first study to analyse the impact of the screening type on benign breast disease prognosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Readmissions and complications in breast ductal carcinoma in situ, A retrospective study comparing screen- and non-screen-detected patients

  • Politi, Julieta|||0000-0001-7315-034X
  • Sala, Maria|||0000-0002-9955-8746
  • Domingo, Laia|||0000-0003-4420-0891
  • Vernet-Tomas, Maria|||0000-0002-5575-2475
  • Román, Marta|||0000-0001-9076-8918
  • Macià Guilà, Francesc|||0000-0002-6090-5894
  • Castells, Xavier|||0000-0002-2528-0382
Population-wide mammographic screening programs aim to reduce breast cancer mortality. However, a broad view of the harms and benefits of these programs is necessary to favor informed decisions, especially in the earliest stages of the disease. Here, we compare the outcomes of patients diagnosed with breast ductal carcinoma in situ in participants and non-participants of a population-based mammographic screening program. A retrospective cohort study of all patients diagnosed with breast ductal carcinoma in situ between 2000 and 2010 within a single hospital. A total of 211 patients were included, and the median follow-up was 8.4 years. The effect of detection mode (screen-detected and non-screen-detected) on breast cancer recurrences, readmissions, and complications was evaluated through multivariate logistic regression analysis. In the majority of women, breast ductal carcinoma in situ was screen-detected (63.5%). Screen-detected breast ductal carcinoma in situ was smaller in size compared to those non-screen-detected (57.53% < 20 mm versus 78.03%, p = 0.002). Overall, breast-conserving surgery was the most frequent surgery (86.26%); however, mastectomy was higher in non-screen-detected breast ductal carcinoma in situ (20.78% versus 9.7%, p = 0.024). Readmissions for mastectomy were more frequent in non-screen-detected breast ductal carcinoma in situ. Psychological complications, such as fatigue, anxiety, and depression, had a prevalence of 15% within our cohort. Risk of readmissions and complications was higher within the non-screen-detected group, as evidenced by an odds ratio = 6.25 (95% confidence interval = 1.95-19.99) for readmissions and an odds ratio = 2.41 (95% confidence interval = 1.95-4.86) for complications. Our findings indicate that women with breast ductal carcinoma in situ breast cancer diagnosed through population-based breast cancer screening program experience a lower risk of readmissions and complications than those diagnosed outside these programs. These findings can help aid women and health professionals make informed decisions regarding screening.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening

  • Louro, Javier|||0000-0002-2985-3301
  • Román, Marta|||0000-0001-9076-8918
  • Posso, Margarita|||0000-0002-5053-257X
  • Vázquez, Ivonne|||0000-0002-5305-1560
  • Saladié, Francina|||0000-0002-1783-4066
  • Rodríguez Arana, Ana|||0000-0003-3115-0178
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Domingo, Laia|||0000-0003-4420-0891
  • Baré i Mañas, Marisa|||0000-0001-8085-2833
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Vernet-Tomas, Maria|||0000-0002-5575-2475
  • Sala, Maria|||0000-0002-9955-8746
  • Castells, Xavier|||0000-0002-2528-0382
Several studies have proposed personalized strategies based on women's individual breast cancer risk to improve the effectiveness of breast cancer screening. We designed and internally validated an individualized risk prediction model for women eligible for mammography screening. Retrospective cohort study of 121,969 women aged 50 to 69 years, screened at the long-standing population-based screening program in Spain between 1995 and 2015 and followed up until 2017. We used partly conditional Cox proportional hazards regression to estimate the adjusted hazard ratios (aHR) and individual risks for age, family history of breast cancer, previous benign breast disease, and previous mammographic features. We internally validated our model with the expected-to-observed ratio and the area under the receiver operating characteristic curve. During a mean follow-up of 7.5 years, 2,058 women were diagnosed with breast cancer. All three risk factors were strongly associated with breast cancer risk, with the highest risk being found among women with family history of breast cancer (aHR: 1.67), a proliferative benign breast disease (aHR: 3.02) and previous calcifications (aHR: 2.52). The model was well calibrated overall (expected-to-observed ratio ranging from 0.99 at 2 years to 1.02 at 20 years) but slightly overestimated the risk in women with proliferative benign breast disease. The area under the receiver operating characteristic curve ranged from 58.7% to 64.7%, depending of the time horizon selected. We developed a risk prediction model to estimate the short- and long-term risk of breast cancer in women eligible for mammography screening using information routinely reported at screening participation. The model could help to guiding individualized screening strategies aimed at improving the risk-benefit balance of mammography screening programs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biomarkers expression in benign breast diseases and risk of subsequent breast cancer, a case-control study

  • Posso, Margarita|||0000-0002-5053-257X
  • Corominas, Josep
  • Serrano, Laia
  • Román, Marta|||0000-0001-9076-8918
  • Torá-Rocamora, Isabel|||0000-0002-5946-4569
  • Domingo, Laia|||0000-0003-4420-0891
  • Romero, Anabel
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Vernet-Tomas, Maria|||0000-0002-5575-2475
  • Baré i Mañas, Marisa|||0000-0001-8085-2833
  • Vidal, Carmen|||0000-0003-2768-2710
  • Sánchez Movellán, Mar
  • Saladié, Francina|||0000-0002-1783-4066
  • Natal, Carmen|||0000-0003-0204-3947
  • Ferrer, Joan
  • Servitja, Sonia|||0000-0001-6988-4519
  • Sala, Maria|||0000-0002-9955-8746
  • Castells, Xavier|||0000-0002-2528-0382
  • Buron, Andrea|||0000-0003-3590-1303
  • Rodríguez-Arana, A.
  • Romero, A.
  • Vernet, M.
  • Andreu, Xavier
  • Milà, N.
  • López Vilaró, Laura|||0000-0002-5428-8017
  • Fernández-Somoano, A.
  • Galceran, Jaume|||0000-0002-1584-7293
  • Espinàs, J.A.
Women with benign breast diseases (BBD) have a high risk of breast cancer. However, no biomarkers have been clearly established to predict cancer in these women. Our aim was to explore whether estrogen receptor (ER), progesterone receptor (PR), and Ki67 expression stratify risk of breast cancer in screened women with BBD. We conducted a nested case-control study. Women with breast cancer and prior BBDs (86 cases) were matched to women with prior BBDs who were free from breast cancer (172 controls). The matching factors were age at BBD diagnosis, type of BBD, and follow-up time since BBD diagnosis. ER, PR, and Ki67 expression were obtained from BBDs' specimens. Conditional logistic regression was used to estimate odds ratios (ORs), and 95% confidence intervals (CIs) of breast cancer risk according to ER, PR, and Ki67 expression. Women with.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long-Term Risk of Breast Cancer after Diagnosis of Benign Breast Disease by Screening Mammography

  • Román, Marta|||0000-0001-9076-8918
  • Louro, Javier|||0000-0002-2985-3301
  • Posso, Margarita|||0000-0002-5053-257X
  • Vidal, Carmen|||0000-0003-2768-2710
  • Bargalló, Xavier
  • Vázquez, Ivonne|||0000-0002-5305-1560
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Alcántara Souza, Rodrigo|||0000-0003-4365-5640
  • Saladié, Francina|||0000-0002-1783-4066
  • del Riego, Javier|||0000-0001-9200-3505
  • Peñalva, Lupe
  • Sala, Maria|||0000-0002-9955-8746
  • Castells, Xavier|||0000-0002-2528-0382
Assessing the long-term risk of breast cancer after diagnosis of benign breast disease by mammography is of utmost importance to design personalised screening strategies. We analysed individual-level data from 778,306 women aged 50-69 years with at least one mammographic screening participation in any of ten breast cancer screening centers in Spain from 1996 to 2015, and followed-up until 2017. We used Poisson regression to compare the rates of incident breast cancer among women with and without benign breast disease. During a median follow-up of 7.6 years, 11,708 (1.5%) women had an incident of breast cancer and 17,827 (2.3%) had a benign breast disease. The risk of breast cancer was 1.77 times higher among women with benign breast disease than among those without (95% CI: 1.61 to 1.95). The relative risk increased to 1.99 among women followed for less than four years, and remained elevated for two decades, with relative risk 1.96 (95% CI: 1.32 to 2.92) for those followed from 12 to 20 years. Benign breast disease is a long-term risk factor for breast cancer. Women with benign breast disease could benefit from closer surveillance and personalized screening strategies.